Biosimilar Doubleheader: Amgen's Humira Competitor Pitching First To FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Arthritis Advisory Committee will preside at back-to-back biosimilar reviews for Amgen's ABP 501 and Sandoz's GP2015, which references Enbrel, in mid-July.
You may also be interested in...
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Time and again, FDA officials had to explain the importance of the analytical characterization data in the biosimilar development paradigm.
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Time and again, FDA officials had to explain the importance of the analytical characterization data in the biosimilar development paradigm.
Biosimilars: Does FDA Caution Make Advisory Committee A Rubber Stamp?
Like biosimilar candidates Zarxio and Inflectra before it, Amgen's ABP 501 enters its advisory committee review with FDA's full-throated endorsement.